** Shares of Structure Therapeutics GPCR.O have more than doubled this year, after declining 33% in 2024

** Structure earlier this month said its experimental oral obesity pill showed 11.3% reduction in weight at 120 mg dose at 36 weeks in mid-stage study

** Shares of other obesity drug developers such as Viking Therapeutics VKTX.O and Altimmune ALT.O are set to end in red

** Weight-loss drug market is surging, with biotech firms racing to win share in sector dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N

** Analysts forecast the industry will generate about $150 billion in annual sales in the next decade

** Shares of Viking are down 12.2% this year after more than doubling in 2024; company said its experimental weight-loss pill helped patients lose 12.2% of their body weight in mid-stage trial, missing Wall Street's top-end expectations of 15%

** Shares of Altimmune have fallen 49.9% this year, set for third straight year of declines

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))